Table 4.
Tumor ORR summary
| CMR, n (%) | PMR, n (%) | NMR, n (%) | PD, n (%) | ORR, n (%) | |
|---|---|---|---|---|---|
| Investigator assessment | |||||
| Cohorts 1 and 2 (n = 6) | 1 (17%) | 3 (50%) | 0 (0%) | 2 (33%) | 4 (67%) |
| Cohort 3 and extension (n = 24) | 10 (42%) | 11 (46%) | 2 (8%) | 1 (4%) | 21 (88%) |
| Safety analysis set (n = 30) | 11 (37%) | 14 (47%) | 2 (7%) | 3 (10%) | 25 (83%) |
| Investigator assessment | |||||
| Cohorts 1 and 2 (n = 5) | 1 (20%) | 2 (40%) | 2 (40%) | 0 (0%) | 3 (60%) |
| Cohort 3 and extension (n = 24) | 11 (46%) | 10 (42%) | 0 (0%) | 3 (13%) | 21 (88%) |
| Safety analysis set (n = 29) | 12 (42%) | 12 (42%) | 2 (7%) | 3 (10%) | 24 (83%) |
PD, progressive disease.